-
公开(公告)号:US11566003B2
公开(公告)日:2023-01-31
申请号:US16921297
申请日:2020-07-06
申请人: Genentech, Inc.
发明人: Bryan Chan , Joy Drobnick , Lewis Gazzard , Timothy Heffron , Jun Liang , Sushant Malhotra , Rohan Mendonca , Naomi Rajapaksa , Craig Stivala , John Tellis , Weiru Wang , BinQing Wei , Aihe Zhou , Matthew W. Cartwright , Michael Lainchbury , Emanuela Gancia , Eileen Seward , Andrew Madin , David Favor , Kin Chiu Fong , Yonghan Hu , Andrew Good
IPC分类号: C07D217/22 , A61K31/549 , A61P35/00 , A61K45/06 , C07D401/04 , A61K31/4725 , A61K31/506 , A61K31/501 , C07D471/04 , C07D413/04 , C07D413/14 , A61K31/5377 , C07D417/04 , A61K31/4985 , C07D401/14 , C07D487/04 , A61K31/551 , C07D498/04 , A61K31/5383 , C07D405/14 , C07D519/00 , C07D498/14 , C07D513/04 , A61K31/554 , A61K31/55 , A61K31/472 , C07D409/14 , C07D491/04 , C07D487/14
摘要: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
-
公开(公告)号:US11434250B2
公开(公告)日:2022-09-06
申请号:US16863741
申请日:2020-04-30
申请人: Genentech, Inc.
发明人: Marian C. Bryan , Joy Drobnick , James Richard Kiefer, Jr. , Aleksandr Kolesnikov , Naomi S. Rajapaksa
IPC分类号: C07D519/00 , A61P1/04 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/06 , A61P25/00 , A61P25/04 , A61P29/00 , A61P35/00 , A61P37/02 , A61P37/06 , A61P43/00
摘要: Compounds of Formula I and methods of use as Interleukin-1 Receptor Associated Kinase 4 (IRAK4) inhibitors are described herein.
-
公开(公告)号:US10407424B2
公开(公告)日:2019-09-10
申请号:US15942321
申请日:2018-03-30
申请人: Genentech, Inc.
发明人: Bryan Chan , Naomi Rajapaksa , Michael Siu , Craig Stivala , John Tellis , Weiru Wang , BinQing Wei , Aihe Zhou , Matthew W. Cartwright , Emanuela Gancia , Graham Jones , Blake Daniels , Michael Lainchbury , Andrew Madin , Eileen Seward , David Favor , Kin Chiu Fong , Andrew Good , Yonghan Hu , Baihua Hu , Aijun Lu , Joy Drobnick , Lewis Gazzard , Timothy Heffron , Malcolm Huestis , Jun Liang , Sushant Malhotra , Rohan Mendonca
IPC分类号: C07D471/04 , A61K31/55 , A61P35/00 , A61K31/444 , A61K31/4375 , A61K31/506 , C07D519/00 , A61K31/4545 , A61K31/4725 , A61K31/5383 , A61K31/496 , A61K31/5377 , A61K31/5025 , A61K31/551 , A61K45/06
摘要: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
-
公开(公告)号:US20150031674A1
公开(公告)日:2015-01-29
申请号:US14340792
申请日:2014-07-25
申请人: GENENTECH, INC.
发明人: Joachim Rudolph , Lewis J. Gazzard , James J. Crawford , Chudi Ndubaku , Joy Drobnick , Wendy Lee
IPC分类号: C07D471/04
CPC分类号: C07D471/04
摘要: Compounds having the formula I wherein R1, R2, R3, R4, R5, Ra, Rb, Rc, Rd, Re, n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
摘要翻译: 具有式I的化合物,其中R1,R2,R3,R4,R5,Ra,Rb,Rc,Rd,Re,n,r,s和t如本文所定义,哪些化合物是PAK1的抑制剂。 还公开了用于治疗癌症和过度增殖性疾病的组合物和方法。
-
公开(公告)号:US20220332718A1
公开(公告)日:2022-10-20
申请号:US17172766
申请日:2021-02-10
申请人: Genentech, Inc.
发明人: Marian C. Bryan , Alberto Gobbi , James Richard Kiefer, Jr. , Aleksandr Kolesnikov , Alan G. Olivero , Joy Drobnick , Jun Liang , Naomi Rajapaksa , Chudi Ndubaku , Jianwen Feng
IPC分类号: C07D487/04 , A61P37/02 , A61P35/00 , C07D519/00 , A61P29/00
摘要: A method for treating an inflammatory or autoimmune disease with compounds of Formula 0, Formula I, and Formula II and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
-
公开(公告)号:US11034698B2
公开(公告)日:2021-06-15
申请号:US16715933
申请日:2019-12-16
申请人: Genentech, Inc.
发明人: Marian C. Bryan , Steven Do , Joy Drobnick , Alberto Gobbi , Tamiko Katsumoto , James Richard Kiefer, Jr. , Jun Liang , Naomi S. Rajapaksa , Yongsheng Chen , Liqiang Fu , Kwong Wah Lai , Zhiguo Liu , John Wai , Fei Wang
IPC分类号: C07D487/04 , C07D519/00
摘要: Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
-
公开(公告)号:US09440976B2
公开(公告)日:2016-09-13
申请号:US14743835
申请日:2015-06-18
申请人: Genentech, Inc.
发明人: Hazel Joan Dyke , Lewis Gazzard , Karen Williams , Huifen Chen , Samuel Kintz , Joy Drobnick , Joseph P. Lyssikatos , Simon Goodacre , Calum Macleod , Charles Ellwood
IPC分类号: C07D471/14 , C07D453/02 , A61K31/5377 , C07D519/00 , A61K31/4375 , A61K31/439 , A61K31/4545 , A61K31/496 , A61K31/55 , A61K45/06
CPC分类号: C07D471/14 , A61K31/4375 , A61K31/439 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D453/02 , C07D519/00
摘要: The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
摘要翻译: 本发明涉及可用作激酶抑制剂的式(I),(I-a)和(I-b)的1,7-二氮杂咔唑化合物,更具体地用作检查点激酶1(chk1)抑制剂,因此可用作癌症治疗剂。 本发明还涉及包含这些化合物的组合物,更具体地是包含这些化合物的药物组合物以及使用该组合物治疗各种形式的癌症和过度增殖性疾病的方法,以及将该化合物用于体外,原位和体内诊断或 治疗哺乳动物细胞或相关病理状况。
-
公开(公告)号:US20210332064A1
公开(公告)日:2021-10-28
申请号:US17220307
申请日:2021-04-01
申请人: Genentech, Inc.
发明人: Jun Liang , Rohan V. Mendonca , Michael Siu , John Tellis , Weiru Wang , BinQing Wei , Bryan Chan , Edna F. Choo , Joy Drobnick , Lewis J. Gazzard , Timothy Heffron
IPC分类号: C07D498/04 , C07D401/04 , C07D401/14 , C07D519/00
摘要: 3-Carbonylaminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylaminoisoquinoline compounds.
-
公开(公告)号:US11034692B1
公开(公告)日:2021-06-15
申请号:US16542129
申请日:2019-08-15
申请人: Genentech, Inc.
发明人: Bryan Chan , Blake Daniels , Joy Drobnick , Lewis Gazzard , Timothy Heffron , Malcolm Huestis , Jun Liang , Sushant Malhotra , Rohan Mendonca , Naomi Rajapaksa , Michael Siu , Craig Stivala , John Tellis , Weiru Wang , BinQing Wei , Aihe Zhou , Matthew W. Cartwright , Emanuela Gancia , Graham Jones , Michael Lainchbury , Andrew Madin , Eileen Seward , David Favor , Kin Chiu Fong , Andrew Good , Yonghan Hu , Baihua Hu , Aijun Lu
IPC分类号: C07D471/04 , A61K45/06 , A61P35/00 , A61K31/444 , A61K31/4375 , A61K31/506 , C07D519/00 , A61K31/4545 , A61K31/4725 , A61K31/5383 , A61K31/496 , A61K31/5377 , A61K31/5025 , A61K31/551 , A61K31/55
摘要: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
-
公开(公告)号:US10988478B1
公开(公告)日:2021-04-27
申请号:US16775650
申请日:2020-01-29
申请人: Genentech, Inc.
发明人: Marian C. Bryan , Alberto Gobbi , James Richard Kiefer, Jr. , Aleksandr Kolesnikov , Alan G. Olivero , Joy Drobnick , Jun Liang , Naomi Rajapaksa , Chudi Ndubaku , Jianwen Feng
IPC分类号: C07D487/04 , C07D519/00 , A61P35/00 , A61P37/02 , A61P29/00
摘要: Compounds of Formula 0, Formula I, and Formula II and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
-
-
-
-
-
-
-
-
-